Ulipristal (ellaone ) for post-coital contraception
|
|
- Percival Simmons
- 5 years ago
- Views:
Transcription
1 for post-coital contraception Author: William Horsley Lead Pharmacist for NETAG September 2009
2 Summary Ulipristal is a first-in-class progesterone receptor modulator licensed for post coital ( emergency ) contraception up to 120 hours (5 days) following unprotected intercourse. Ulipristal has demonstrated efficacy in non-comparative and randomised comparative studies versus levonorgestrel. The results indicate that it is at least as effective as levonorgestrel. The adverse effect profile for ulipristal is similar to that seen with levonorgestrel, with mild gastrointestinal symptoms and disruption to normal menstrual patterns the most frequently occurring and common effects. The effects of inadvertent ulipristal exposure in utero are not known. Ulipristal is about three times the cost of levonorgestrel at per dose versus 5.37 per dose. Levonorgestrel is widely provided within NHS North East. It is licensed for use up to 72 hours (3 days) following unprotected intercourse. It is available from several sources, many without the need for prescription. Ulipristal will initially be available on prescription only. North East Treatment Advisory Group. September
3 Background and introduction Emergency contraception is the lay term applied to any contraceptive intervention that is made post-coitus (more accurately referred to as post-coital contraception [PCC]). There are many different reasons why PCC may be required. Current treatment options consist of either: Levonorgestrel 1.5 mg (Levonelle ) or, Insertion of an intra-uterine device (IUD) Levonorgestrel is considered the first-line treatment option compared with an IUD because of its ease of access (it can even be purchased without a prescription), ease of administration requiring no third party assistance and being non-invasive, an acceptably high level of efficacy, and relatively low cost. Levonorgestrel is taken as a single dose as soon as possible, and no later than 72 hours, postcoitus. If PCC is required beyond the 72 hour window afforded by levonorgestrel then an IUD can be inserted up to five days post-coitus. Levonorgestrel is estimated to prevent about 85% of conceptions as it is used in practice. However it is also widely considered to be more effective in the first 24 hours (95%) and less effective in the last 24 hours of that period (58%) so that expediency of consumption is advised. An IUD is 100% effective at whatever point in the five days post-coital period it is inserted. In practice, levonorgestrel is often used offlicense for PCC up to 120 hours (5 days), although it is not known what level of efficacy it provides beyond 72 hours. 1 Normal sperm can survive in the female reproductive tract and retain the ability to fertilize an egg for at least three, and up to five, days. An oocyte can be successfully fertilised for only approximately 12 to 24 hours after it has been released. Although not specifically stated, it is assumed that for this reason several published studies of PCC in women are conducted up to a maximum of 120 hours post-coitus. 2,3 is a first-in-class progesterone receptor modulator licensed for contraception up to 120 hours (five days) post-coitus. It is taken as a single 30 mg dose, containing micronised drug particles. 4 Its mode of action has not been fully elicited but its principal mode of action is believed to be via progesterone receptor antagonism thereby preventing the pro-pregnancy effects of progesterone. Specifically, it results in delayed ovulation. Ulipristal has also demonstrated some progesterone agonistic effects in vitro. 5-7 Ulipristal has been investigated for a number of other indications including prospective contraception and uterine fibroids/leiomyoma. 5-7 The purpose of this report is to appraise the evidence for the safety and efficacy of ulipristal when used for contraceptive purposes, advise on the potential financial implications and inform a recommendation on the use of ulipristal to be made by the North East Treatment Advisory Group. North East Treatment Advisory Group. September
4 Clinical evidence Two key phase II studies 3,8 and two phase III studies 3,9 of the use of ulipristal as a method of PCC have been completed. Different formulations of ulipristal were used in the studies with initial research utilising a 50 mg tablet, whereas the phase III studies used a 30 mg tablet containing micronised drug particles. The two formulations are considered to be bioequivalent. 3 One phase II and one phase III study were comparative studies versus levonorgestrel. The data from these two studies has been combined in an as yet unpublished meta-analysis. In the only published evidence, a phase II study, randomised 1,672 women requiring PCC within 72 hours to treatment with ulipristal 50 mg (n = 832) or levonorgestrel 1.5 mg taken as two 750 microgram doses approximately 12 hours apart (n = 840). 8 Patients had a mean age of 24 years (minimum 18), were predominantly white (73%), and well educated (86% with college or higher education). Efficacy results are based on 792 and 786 patients respectively with omissions due only to loss to follow-up. The trial was designed to demonstrate the non-inferiority of ulipristal compared with levonorgestrel. Twenty-six pregnancies occurred, 12 in patients treated with ulipristal and 14 with levonorgestrel, corresponding to rates of 1.5% and 1.8% respectively (p > 0.05). Based on pre-treatment blood test results and ultra-sound scans, four pregnancies in the ulipristal group and one in the levonorgestrel group were subsequently found to have occurred prior to study entry. Exclusion of these patients plus patients who had used additional PCC within the same cycle resulted in 7 (0.9%) and 13 (1.7%) pregnancies respectively. Ulipristal was calculated to have prevented 85% of expected pregnancies compared with 69% in levonorgestrel patients (p > 0.05). The other phase II study of ulipristal for PCC is not published. The following results have been obtained from the European Medicines Agency public assessment report (EPAR) where the study is referred to as HRA Four hundred patients (mean age 24 years, 70% white) were randomised to PCC treatment with either ulipristal 50 mg or ulipristal (micronised) 10 mg, taken within 72 hours of coitus. The micronised formulation was found to be non-significantly inferior to the standard preparation with an estimated 52% of pregnancies prevented compared with 76%. The phase III studies are also unpublished and again results are obtained from the EPAR and additionally unpublished data from the license holder. The first study is referred to as HRA and was an open-label non-comparative study of ulipristal 30 mg (micronised) taken within 48 to 120 hours post-coitus. 3 1,623 patients were enrolled, 1,533 were treated and included in the intention-totreat population. Within the intention-to-treat population there were 29 pregnancies, yielding a rate of 2.17% compared with an expected rate of 5.64%. North East Treatment Advisory Group. September
5 The second phase III study is referred to in the EPAR as HRA Data is currently available only from conference abstracts and unpublished commercial literature. 9,10 In this study patients were randomised to ulipristal 30 mg (n = 939) or levonorgestrel 1.5 mg (n = 954) within 120 hours of coitus. In the whole patient population there were 15 pregnancies in the ulipristal group (1.6%) and 25 in the levonorgestrel group (2.6%). The difference was not significant (p > 0.05). In the subset of patients treated up to 72 hours (n = 843 and 851 respectively) there were 15 pregnancies in the ulipristal group (1.8%) and 22 in the levonorgestrel group (2.6%). The difference was not significant (p > 0.05). Non-inferiority of ulipristal compared with levonorgestrel was adequately demonstrated. A meta-analysis of the phase II and phase III comparative studies, each involving different formulations of ulipristal and a different regimen for levonorgestrel, was also presented at the same conference in September ,11 The data is currently available in abstract and cannot be fully appraised. The evidence shows that over the 120 hour period ulipristal is significantly more effective than levonorgestrel at producing a reduced pregnancy rate. Safety Data relating to the adverse effects of ulipristal are not readily available as many of the studies have not yet been published. In the published phase II comparative study the incidence of adverse effects appears to be similar in both groups. The most common observed adverse effects are headache, nausea, vomiting, and mild abdominal pain. 8 In the phase III comparative study the most common adverse effects with ulipristal and levonorgestrel were, respectively; headache (both 19%), dysmenorrhea (13% and 14%), nausea (13% and 11%), abdominal pain (5% and 7%), dizziness (both 5%), fatigue (6% and 5%), and upper abdominal pain (3% and 4%). 10 Effects resulting in disruption to the normal menstrual cycle appear common. It has been observed that ulipristal results in an increase to the duration of the average menstrual cycle of two days. This would be expected with its primary mode of action believed to be due to ovulatory delay. 3 Additionally, the product data sheet provides the following statement: 4 The majority of women (80.8%) in the phase III study had their next menstrual period at the expected time or within ± 7 days, while 6.1% experienced menses more than 7 days earlier than expected and 19.2% had a delay of more than 7 days beyond the anticipated onset of menses. This delay was greater than 20 days in 5.1% of the women, and 0.5 % of women experienced a delay of more than 60 days beyond the anticipated onset of menses. Menstrual volume was reported by 79.0% of women as normal, 16.0% as heavy and 5.0% as spotting. A minority (8.7%) of women reported intermenstrual bleeding lasting an North East Treatment Advisory Group. September
6 average of 2.4 days. In a majority of cases (91.8%), this bleeding was reported as spotting. Among the women who received Ellaone in the phase III study, only 5 (0.3%) reported heavy intermenstrual bleeding. Little is known about the long term effects of ulipristal but in clinical use patients would be expected to be exposed to only small cumulative life time doses with long latent periods between doses. A three month study exposed healthy female patients to low daily doses (2.5, 5 or 10 mg). This found no significant increase in adverse effects compared with placebo other than an increased incidence of acne for patients taking 5 or 10 mg of ulipristal. Other common effects included headache (~40%), dysmenorrhea (~20%), breast pain (~10%), and pelvic pain (~10%). There were no blood pressure changes or weight gain, and no changes observed with liver function tests, electrolyte screens, creatinine levels, blood sugar levels, lipid screens, cortisol, prolactin, or testosterone levels. 12 One important aspect that has not been adequately addressed is the outcomes of pregnancies that are inadvertently exposed to ulipristal. Most instances of inadvertent exposure would likely occur in the first trimester, and indeed within the first few weeks of the first trimester, a period during which embryonic development is particularly sensitive. The EPAR states that of four known births following in utero ulipristal exposure at various statim doses all were normal. Summary of evidence There are concerns of significant methodological flaws in the calculation of expected pregnancy rates as this relies on the theory of a six-day fertile window per cycle identified with reference to the point of ovulation. However the time of ovulation is not known and is therefore assumed to be fourteen days prior to menstrual bleeding for women with consistent cycle duration. All studies recruited only women who reported consistent cycles. This problem is common to all studies of pharmacological contraception and there is little that can be done to overcome it in practice. 3 This places even greater value on data from the randomised comparative studies. The evidence base for ulipristal demonstrates that it confers an acceptably high rate of efficacy which appears to be at least as effective as levonorgestrel. However only one study has been published and evidence from the remaining studies is taken from a secondary source and unpublished sources such as conference abstracts and commercial literature. The published comparative study made use of a formulation of ulipristal that will not be available, and an obsolete regimen of levonorgestrel. Both are considered to be equivalent to the available preparation and the standard regimen respectively. The safety profile of ulipristal appears similar to that of levonorgestrel although there is still uncertainty regarding inadvertent exposure in utero. North East Treatment Advisory Group. September
7 Cost analysis The price of ellaone is compared with 5.37 for Levonelle. IUDs currently available on NHS prescription range in cost from 8 to 27 (median value 10.53). However, about 15% of Levonelle primary care prescriptions within NHS North East are inadvertently prescribed as the over-the-counter Levonelle-One Step proprietary brand, at a cost of ,14 In the last financial year (April 2008 to March 2009) nearly 10,000 doses of levonorgestrel 1.5 mg were dispensed on primary care prescriptions within NHS North East. 14 Additionally, most areas have in place arrangements for provision other than via primary care prescriptions (e.g. direct supply from a community pharmacy or through a patient group directive by a nurse or health visitor). Other sources of provision at NHS expense include acute hospital trusts (e.g. via an accident and emergency department), and specialist clinics and centres (e.g. NHS walk-in centres). A sample of data from six predominantly urban primary care trusts within NHS North East indicates that levonorgestrel supplied directly from pharmacies at local NHS expense (i.e. not private purchases; for example via patient group directives or specially commissioned services) account for a greater volume than that which is prescribed on primary care prescriptions (i.e. four times the prescription volume). No data was obtained concerning the volume of dispensing/supply via other sources. Unfortunately the total demand within NHS North East for PCC, as measured via provision of levonorgestrel and IUDs for PCC, cannot be accurately estimated. It can be stated that demand for PCC is a frequent occurrence especially within certain patient groups (e.g. young females). The evidence from clinical studies of ulipristal of up to 120 hours demonstrated that only about 10% of supplies were made in the period between 72 and 120 hours. 3,8,10 This rate may be subject to patient recall bias and deliberate manipulation. If this rate is replicated in practice it would mean that 90% of demand can be satisfied with use of levonorgestrel within its product license. The remaining 10% could be treated with levonorgestrel off-license, IUD insertion, or remain untreated with subsequent sequelae including no pregnancy, termination or delivery. North East Treatment Advisory Group. September
8 Relevant substitution costs depending on treatment choices include: 13,15 a. For each ulipristal prescription instead of a prescription for levonorgestrel an additional is incurred. b. For each ulipristal prescription instead of a prescription for an IUD an additional 6.00 is incurred (range - 10 to 9) although this will likely be more than offset in terms of reduced labour input and other resources required for insertion of an IUD. An IUD will result in contraception for as long as it remains in situ, often between five and ten years. c. A day case admission for an early stage medically treated termination costs 502, and from 514 to 649 for day case surgical terminations. Any admissions that are not dealt with as day cases will incur additional costs. Use of ulipristal will result in less tangible costs arising from the need for a prescription. For example, patients may have to book an appointment to see a general practitioner or a nurse prescriber, whereas currently levonorgestrel can be accessed from several sources without appointment. Stated prices do not include VAT. Drugs and appliances that are not prescribed on a primary care prescription will be subject to VAT, which will be 17.5% from 1 st January Practical considerations The availability of a PCC pill that can be taken up to 120 hours post-coitus and which does not appear to demonstrate declining efficacy within that period could have subtle and unintended consequences on patient and prescriber behaviour. Levonorgestrel is widely available from a range of different sources. Many of these sources of supply will not initially be available with ulipristal. This could result in increased demand for medical consultations. The product data sheet advises [if experiencing a] delay of more than 7 days in next menstrual period, abnormal bleeding at the expected date of menses, or symptoms of pregnancy, pregnancy should be excluded by a pregnancy test. As these effects are relatively common following use of ulipristal (~20%) this could result in a large number of patients seeking pregnancy tests, with the cost potentially falling on NHS budgets. Additionally, there will be psychological effects such as worry, panic, and anxiety, associated with any delayed menstruation. As with levonorgestrel, nausea and vomiting are relatively common adverse effects with ulipristal. If patients vomit within three hours of taking ulipristal an additional dose is required to ensure therapeutic efficacy is maintained. 4 North East Treatment Advisory Group. September
9 Points to consider Ulipristal represents a new oral PCC option that is licensed for use up to 120 hours post-coitus. Evidence indicates that it is at least as effective as levonorgestrel and does not appear to demonstrate reduced efficacy with time. It has a similar adverse effect to levonorgestrel. The evidence for the efficacy of ulipristal is derived from a population aged between 18 and 35 years. Use outside of this age group would not be evidence-based, although there is little reason to expect the efficacy to be different. Ulipristal is about three times as expensive, per dose, than levonorgestrel, and about 1.5 to 2 times as expensive as an IUD. Levonorgestrel is widely accessible via a number of established routes. Ulipristal would initially be available only via prescription. The effects of inadvertent in utero exposure to ulipristal are not known. Disclosure The author has no relevant conflicts of interest to declare. North East Treatment Advisory Group. September
10 References 1. Guillebaud J. Contraception: Your questions answered. Churchill Livingstone, London, Wilcox AJ, Weinberg CR, Baird DD. Post-ovulatory ageing of the human oocyte and embryo failure. Human Reproduction 1998;13(2): European Medicines Agency. CHMP Assessment Report for Ellaone. Document reference EMEA/261787/ Summary of product characteristics. Ellaone (HRA Pharma). Accessed via the European Medicines Agency 5. Chabber-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Human Reproduction Update 2005;11(3): Blithe DL, Nieman LK, Blye Rp et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 2003;68: Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA) Steroids 2003;68: Creinin MD, Schlaff W, Archer DF et al. Progesterone receptor modulator for emergency contraception. Obstetrics & Gynecology 2006;108(5): Cameron S, Glasier A, Fine P, Mathe H, Gainer E. Ulipristal acetate compared to levonorgestrel for emergency contraception within five days of unprotected intercourse: A randomised controlled trial. Abstract presented at the 8 th Congress of the European Society of Gynecology, September Unpublished data on file courtesy of HRA Pharma, August Ulmann A, Scherrer B, Mathe H, Gainer E. Meta-analysis of emergency contraception trials comparing ulipristal acetate with levonorgestrel. Abstract presented at the 8 th Congress of the European Society of Gynecology, September Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebo-controlled trial. Journal of Endocinology and Metabolism 2007;92(9): NHS dictionary of medicines and devices Data provided by the Regional Drug & Therapeutics Centre (Newcastle) Department of Health. Payment by results tariff North East Treatment Advisory Group. September
Ulipristal Acetate (ellaone )
FACULTY OF SEXUAL & REPRODUCTIVE HEALTHCARE Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit A unit funded by the FSRH and supported by NHS Greater Glasgow & Clyde to provide guidance
More informationEmergency Contraception THE FACTS
Emergency Contraception Quick Facts What is it? Emergency contraception is birth control that you use after you have had unprotected sex--if you didn t use birth control or your regular birth control failed.
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OR ADMINISTRATION OF LEVONORGESTREL 1500 MICROGRAM TABLET (e.g LEVONELLE 1500 ) PGD
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorized by their organization to practice under it. The most recent and in date final signed version
More informationEmergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains
More informationNew Zealand Datasheet
New Zealand Datasheet 1 PRODUCT NAME POSTINOR-1 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Levonorgestrel 1.5 mg 3 PHARMACEUTICAL FORM Each round white tablet contains 1.5 mg of levonorgestrel. The tablet
More informationPatient Group Direction for the administration of Levonorgestrel Emergency Contraception for Community Pharmacy
Patient Group Direction for the administration of Levonorgestrel for Community Pharmacy Author Corporate Lead Chris Toothill (Medicines Management Pharmacist, Governance and Risk, Leeds Community Healthcare
More informationDoes use of emergency contraception prevent unintended pregnancy? Anna Glasier
Does use of emergency contraception prevent unintended pregnancy? Anna Glasier There has never been a placebo controlled trial of emergency contraception So to assess whether EC works we have to look to
More informationUpdate on EC methods and mechanism of action. Emergency Contraception (EC) Historical EC (1) Historical EC (2) Current EC Options
ESC Meeting 2016 Update on EC methods and mechanism of action Dr. Raymond Li MBBS, MMedSC, FRCOG, FHKAM (O&G) Cert RCOG/HKCOG (Reprod Med) Department of O&G, The University of Hong Kong The Family Planning
More informationNHS Lothian Patient Group Direction Version: 007. Title: Levonorgestrel 1500mcg for Emergency Contraception
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LEVORGESTREL 1500mcg FOR EMERGENCY CONTRACEPTION BY DESIGNATED HEALTHCARE PROFESSIONALS PROVIDING SEXUAL HEALTH SERVICES, UNSCHEDULED CARE SERVICES OR
More informationLevosert levonorgestrel 20mcg/24hour intrauterine device
Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert
More informationPATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)
PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) VALID FROM: 1 st July 2016 REVIEWED DATE: 30 th June 2019 This
More informationInformation Booklet. Exploring the causes of infertility and treatment options.
Information Booklet Exploring the causes of infertility and treatment options www.ptafertility.co.za info@ptafertility.co.za +27 12 998 8854 Faith is taking the first step even if you don t see the whole
More informationthe IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to
your guide to Helping you choose the method of contraception that s best for you IUD IUD the e IUD IU IUD the IUD 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that s put
More informationManagement of Emergency Contraception (EC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of Emergency Contraception (EC) The risks and benefits of an IUD or oral EC should be discussed and documented (see appendix). Reasonable measures
More informationMMPr001 EMERGENCY CONTRACEPTION PROTOCOL
MMPr001 EMERGENCY CONTRACEPTION PROTOCOL MMPr001 Emergency Contraception - (Sept18-Sept20) Page 1 of 8 Table of Contents MMPr001 EMERGENCY CONTRACEPTION PROTOCOL... 1 Why we need this protocol... 3 What
More informationPatient Group Direction for LEVONELLE (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationMMPr001 EMERGENCY CONTRACEPTION PROTOCOL
MMPr001 EMERGENCY CONTRACEPTION PROTOCOL Table of Contents MMPr001 EMERGENCY CONTRACEPTION PROTOCOL... 1 Why we need this Protocol... 2 What the Protocol is trying to do... 2 Which stakeholders have been
More informationGuidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception
Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception Pharmaceutical Society of Ireland Version 4 December 2016 Updates made following
More informationApplication for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines
Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;
More informationService Line: Rapid Response Service Version: 2.0 Publication Date: November 29, 2018 Report Length: 20 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Ulipristal versus Levonorgestrel for Emergency Contraception: A Review of Comparative Clinical Effectiveness and Guidelines Service Line: Rapid
More informationEmergency contraception: Separating fact from fiction
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will prescribe emergency contraception confidently PELIN BATUR, MD, FACP, NCMP Education Director, Primary Care Women s Health, Cleveland Clinic Independence
More informationContraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014
Contraception Tami Allen, RNC OB, MHA Robin Petersen, RN, MSN Perinatal Clinical Nurse Specialist Objectives Discuss the impact of unintended pregnancy in the United States Discuss the risks and benefits
More informationEmergency contraception methods, including oral and
FOCUS Emergency contraception: Oral and intrauterine options Kirsten I Black, Safeera Y Hussainy Background Emergency contraception can be used to prevent pregnancy where contraception has not been used,
More informationPackage leaflet: Information for the user. Levonorgestrel 1.5 mg Tablet. levonorgestrel
Package leaflet: Information for the user Levonorgestrel 1.5 mg Tablet levonorgestrel Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationFertility care for women diagnosed with cancer
Saint Mary s Hospital Department of Reproductive Medicine Information for Patients Fertility care for women diagnosed with cancer Contents Page Overview... 2 Our service... 2 Effects of cancer treatment
More information100% Highly effective No cost No side effects
effective? Advantages Disadvantages How do I get Cost Abstinence For some it can mean no sexual contact. For others it is no sexual intercourse or vaginal penetration. A permanent surgical procedure available
More informationCALDERDALE PRIMARY CARE TRUST
CALDERDALE PRIMARY CARE TRUST PATIENT GROUP DIRECTION FOR THE SUPPLY AND ADMINISTRATION OF MEDICINES BY NON- MEDICAL PERSONNEL Progestogen-only emergency contraception for use in Community Pharmacies APPROVED
More informationLevonorgestrel 1500 micrograms by Community Pharmacists
Patient Group Direction for the supply/administration of by Community Pharmacists Valid from 1st August 2015 to 31st July 2017* This patient group direction must be agreed to and signed by all pharmacists
More informationHALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY. CONTENTS Page
HALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO TREATMENT 3 4. DEFINITION
More informationIntra uterine insemination (IUI) Information for Patients and Partners
Intra uterine insemination (IUI) Information for Patients and Partners What is this leaflet about and who is it for? This leaflet is produced to inform couples undergoing IUI (intrauterine insemination)
More informationMELATONIN Insomnia and Sleep Disorders in Children
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which
More informationDirector of Commissioning, Telford and Wrekin CCG and Shropshire CCG. Version No. Approval Date August 2015 Review Date August 2017
Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services, in Shropshire and Telford and Wrekin Owner(s) Version No. Director of
More informationSummary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well
More informationASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE
ASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE Version 1.0 Page 1 of 11 MARCH 2014 POLICY DOCUMENT VERSION CONTROL CERTIFICATE TITLE Title: Assisted Conception
More informationLEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common
4:15 5 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationlevonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer
levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationFitting of an Intrauterine Device (IUD)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an IUD? An IUD is a small T-shaped plastic and copper device that is put into
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationLong Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator
Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2014 Publication date 30 September 2014 A National Statistics Publication for Scotland
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT ellaone 30 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 30 mg ulipristal acetate. Excipients with known
More informationProsthetic intervertebral disc replacement in the cervical spine: Cost-effectiveness compared with cervical discectomy with or without vertebral
Prosthetic intervertebral disc replacement in the cervical spine: Cost-effectiveness compared with cervical discectomy with or without vertebral fusion Author: William Horsley NHS North East Treatment
More informationBlackpool CCG. Policies for the Commissioning of Healthcare. Assisted Conception
1 Introduction Blackpool CCG Policies for the Commissioning of Healthcare Assisted Conception 1.1 This policy describes circumstances in which NHS Blackpool Clinical Commissioning Group (CCG) will fund
More informationOne-day Essentials Contraception. Dr Paula Briggs, General Practitioner, Clinical Lead Community Sexual Health, Sefton and West Lancashire
One-day Essentials Contraception { Dr Paula Briggs, General Practitioner, Clinical Lead Community Sexual Health, Sefton and West Lancashire 80% women access contraception from their GP Therefore it is
More informationNEW PATIENT DATA SHEET Please complete as best you can. It is not necessary to have all information before speaking with a doctor. PATIENT INFORMATION
NEW PATIENT DATA SHEET Please complete as best you can. It is not necessary to have all information before speaking with a doctor. PATIENT INFORMATION PATIENT NAME DOB AGE PARTNER NAME DOB AGE STREET CITY
More informationCOMMON QUESTIONS ABOUT ACUPUNCTURE & NATUROPATHIC MEDICINE IN IMPROVING FERTILITY
COMMON QUESTIONS ABOUT ACUPUNCTURE & NATUROPATHIC MEDICINE IN IMPROVING FERTILITY How does acupuncture influence the female reproductive system? Acupuncture has been reported to promote the circulation
More informationProduct Information. Confidence that lasts
Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel
More informationCLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR EMERGENCY HORMONAL CONTRACEPTION Levonorgestrel 1500mcg
CLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR EMERGENCY HORMONAL CONTRACEPTION Levonorgestrel 1500mcg Version Control This document is only valid on the day it was printed The current version of this
More informationWHAT ARE CONTRACEPTIVES?
CONTRACEPTION WHAT ARE CONTRACEPTIVES? Methods used to prevent fertilization *Also referred to as birth control methods With contraceptives, it is important to look at what works for you and your body.
More informationSt Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16
St Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16 1 Standard Operating Procedure St Helens CCG NHS Funded Treatment for Sub Fertility Policy Version 1 Implementation Date May 2015 Review
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More information(FIRST) (MIDDLE) (LAST) STREET: CITY: STATE: ZIP CODE:
PATIENT INFORMATION EMAIL: MARITAL STATUS: [ ]MARRIED [ ]SINGLE [ ]DIVORCED [ ]WIDOWED NAME: (FIRST) (MIDDLE) (LAST) STREET: CITY: STATE: ZIP CODE: DOB: PHONE: [ ]Home [ ]Work [ ]Cell PHONE: [ ]Home [
More informationLong Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator
Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2013 Publication date 24 September 2013 A National Statistics Publication for Scotland
More informationWestern Locality Shared care information ~ Gonadorelin Analogues (Gnrh)
Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Specialist: Please complete the Shared Care letter sending a request to GP (see bottom of the page) April 2013 GP: Please indicate
More informationEffectiveness of emergency contraception in women after sexual assault
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2013;40(3):126-130 Effectiveness of emergency contraception in women after sexual assault Dong Seok Choi, Miran Kim, Kyung Joo Hwang,
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationDr Mary Birdsall. Fertility Associates Auckland
Dr Mary Birdsall Fertility Associates Auckland Period Problems Mary Birdsall Medical Director Fertility Associates Auckland Period Problems Basic Physiology No Periods Irregular Periods Heavy Periods
More informationNHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs
NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO
More informationINFERTILITY CAUSES. Basic evaluation of the female
INFERTILITY Infertility is the inability to conceive after 12 months of unprotected intercourse. There are multiple causes of infertility and a systematic way to evaluate the condition. Let s look at some
More informationBuprenorphine used in the treatment of opioid dependence: availability and price
7 th floor Wellington House 133 155 Waterloo Road London SE1 8UG 24 October 2018 Gateway number: L2018-443 Dear Director of Public Health, Buprenorphine used in the treatment of opioid dependence: availability
More informationUnintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use
3:45 4:30 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationEMERGENCY CONTRACEPTION: QUESTIONS AND ANSWERS FOR DECISION-MAKERS
EMERGENCY CONTRACEPTION: QUESTIONS AND ANSWERS FOR DECISION-MAKERS 2013 Publication type: EC Fact Sheet A brief overview of emergency contraception What is emergency contraception? The term emergency contraception
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1.
*40675* 40675 MR-838 (9-2017) WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. I, and (Print Patient s name) (Print
More informationPRODUCT INFORMATION LEVONELLE- 1. LEVONELLE-1 is an emergency oral contraceptive tablet containing the synthetic progestogen, levonorgestrel.
PRODUCT INFORMATION LEVONELLE 1 NAME OF THE DRUG LEVONELLE1 is an emergency oral contraceptive tablet containing the synthetic progestogen, levonorgestrel. Levonorgestrel is a progestogen. The chemical
More informationREPROS THERAPEUTICS. Dedicated to Treating Male and Female Reproductive Disorders. Corporate Presentation. August 2017
REPROS THERAPEUTICS Dedicated to Treating Male and Female Reproductive Disorders Corporate Presentation August 2017 Safe Harbor Any statements made by the Company that are not historical facts contained
More informationLong Acting Reversible Methods of Contraception (LARC) in Scotland
Publication Report Long Acting Reversible Methods of Contraception (LARC) in Scotland Year ending March 2015 Publication date 3 November 2015 A National Statistics Publication for Scotland Contents Introduction...
More informationالحمد هلل رب العالمين والصالة والسالم علي محمد الصادق الوعد األمين اللهم أخرجنا من ظلمات الجهل والوهم إلى نور المعرفة والعلم..
الحمد هلل رب العالمين والصالة والسالم علي محمد الصادق الوعد األمين اللهم أخرجنا من ظلمات الجهل والوهم إلى نور المعرفة والعلم.. سيدنا 11/6/2013 1 Goals of Family Planning services : 1- Enable women and
More informationNew Patient Medical History
New Patient Medical History MR #: Initial Appointment Date: / / Name: Birth Date: / / Address: City: State: Zip: Best Phone # to reach you: ( ) Second contact #: ( ) Email Address: Occupation: Marital
More informationREPROS THERAPEUTICS. Dedicated to Treating Male and Female Reproductive Disorders. Corporate Presentation. September 2017
REPROS THERAPEUTICS Dedicated to Treating Male and Female Reproductive Disorders Corporate Presentation September 2017 Safe Harbor Any statements made by the Company that are not historical facts contained
More informationInfertility Investigations. Patient Information
Infertility Investigations Patient Information Author ID: PH Leaflet Number: Gyn 048 Version: 4 Name of Leaflet: Infertility Investigations Date Produced: March 2017 Review Date: March 2019 Please be aware
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationThe University of Hong Kong Shenzhen Hospital, Shenzhen, China
Human Reproduction, Vol.31, No.6 pp. 1200 1207, 2016 Advanced Access publication on April 6, 2016 doi:10.1093/humrep/dew055 ORIGINAL ARTICLE Fertility control Efficacy of ulipristal acetate for emergency
More informationPatient Group Direction For The Supply Of Levonorgestrel For Emergency Hormonal Contraception By Pharmacists Working Within NHS Grampian
Patient Group Direction For The Supply Of Levonorgestrel For Emergency Hormonal Contraception By Pharmacists Working Within NHS Grampian Co-ordinators: Principal Pharmacist, Pharmacy and Medicines Directorate
More informationACT TRYING TO HAVE A BABY? YOUR STEP-BY-STEP GUIDE TO ASSISTED CONCEPTION THE ACT PATHWAY
ACT TRYING TO HAVE A BABY? YOUR STEP-BY-STEP GUIDE TO CONCEPTION THE ACT PATHWAY ACT HOW TO USE THE ACT PATHWAY BOOKLET Firstly: You are not alone. Up to 1 in 6 couples around the world will experience
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationBrighton & Hove CCG PLS CONFERENCE Dr Carole Gilling-Smith Medical Director
Brighton & Hove CCG PLS CONFERENCE 2016 Dr Carole Gilling-Smith Medical Director FERTILITY CHALLENGES IN THE NHS A TERTIARY CARE PERSPECTIVE LEARNING OBJECTIVES Understand the pathways through assisted
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IVF WITH EMBRYO TRANSFER
*40639* 40639 WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IVF WITH EMBRYO TRANSFER I have requested treatment by the physicians and (Print Patient s name) staff of the Women & Infants Fertility
More informationCommissioning Policy For In Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) within Tertiary Infertility Services
Commissioning Policy For In Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) within Tertiary Infertility Services Reference No: Version: 2 Ratified by: EMSCGP006V2 EMSCG Date ratified:
More informationChapter 7 Infertility, Contraception, and Abortion
Chapter 7 Infertility, Contraception, and Abortion Infertility Incidence Affects about 10% to 15% of reproductive-age population Subfertility: prolonged time to conceive Sterility: inability to conceive
More informationLong Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator
Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2012 Publication date 25 September 2012 A National Statistics Publication for Scotland
More informationIntrauterine (IUI) and Donor Insemination (DI) Policy (excluding In vitro fertilisation (IVF) & Intracytoplasmic sperm injection (ICSI) treatment)
Leicester City Clinical Commissioning Group West Leicestershire Clinical Commissioning Group East Leicestershire and Rutland Clinical Commissioning Group POLICY DOCUMENT Intrauterine (IUI) and Donor Insemination
More informationReview of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016
Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016 INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and
More informationPHARMACY BENEFITS MANAGER
PHARMACY BENEFITS MANAGER CU GME Benefits Office Prescriptions should be obtained at participating pharmacies using your Benefits ID card. A list of participating pharmacies may be obtained by calling
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON INTRAUTERINE DEVICES Boddu Venkata Komali* 1, M. Kalyani
More informationDrug Misuse and Dependence Guidelines on Clinical Management
Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Services, Northern Ireland Drug Misuse and Dependence Guidelines on Clinical Management An Executive
More informationA randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception
BJOG: an International Journal of Obstetrics and Gynaecology May 2002, Vol. 109, pp. 553 560 A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception Premila
More informationContraception. Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine
Contraception Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine Disclosures No financial relationships to disclose I have no commercial, financial, research ties to
More informationWeb Activity: Simulation Structures of the Female Reproductive System
differentiate. The epididymis is a coiled tube found along the outer edge of the testis where the sperm mature. 3. Testosterone is a male sex hormone produced in the interstitial cells of the testes. It
More informationSUBFERTILITY. (Defined as involuntary failure to conceive within 12 months with regular coitus)
SUBFERTILITY (Defined as involuntary failure to conceive within 12 months with regular coitus) Clients attending with fertility concerns should have a medical, drug, menstrual, contraception, social and
More informationPolycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome (PCOS) What are Polycystic Ovaries? Polycystic ovaries are slightly larger than normal ovaries and have twice the number of follicles (small cysts). Polycystic ovaries are very
More informationUnit 6 REPRODUCTIVE SYSTEM Reproductive System Test Bank
Unit 6 REPRODUCTIVE SYSTEM Reproductive System Test Bank Objective 6.01 Describe the basic functions of the reproductive system. 1. Which of the following is a function of the reproductive system? a. Production
More informationFDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections
More informationBiology of fertility control. Higher Human Biology
Biology of fertility control Higher Human Biology Learning Intention Compare fertile periods in females and males What is infertility? Infertility is the inability of a sexually active, non-contracepting
More informationCOMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.
COMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.3 2017 Agreed at Cannock Chase CCG Signature: Designation: Chair of
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationSocial Franchising as a Strategy for Expanding Access to Reproductive Health Services
Social Franchising as a Strategy for Expanding Access to Reproductive Health Services A case study of the Green Star Service Delivery Network in Pakistan Background Pakistan has a population of 162 million
More informationSHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty
WORKING IN PARTNERSHIP WITH SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR 11.25 mg TM ) for precocious puberty NHS Surrey s Medicines Management Committee classification:
More information1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis
1 2 3 1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980 2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet
More informationNRT Voucher redemption scheme service specification
NRT Voucher redemption scheme service specification Updated March 2016 Review date March 2018 Page 1 of 7 1. Introduction The NRT voucher scheme is for NHS Fife stop smoking advisors who have been deemed
More information